cd19 car-t cells long-term efficacy

cd19 car-t cells long-term efficacy

80% Get CAR-T Long-Term Efficacy Wrong for Autoimmune Conditions

Around 80% of clinicians and patients misinterpret the long-term efficacy of CD19 CAR-T therapy for autoimmune disease, assuming remission is short-lived. In reality the durability of response hinges on data that only emerge years after the first infusion, and those figures are now reshaping chronic disease management. Medical Disclaimer: This